The aims of this investigation were: to assess the benefit of long-term treatment with insulin aspart, insulin glulisine or insulin lispro, each compared to a treatment with short-acting human insulin, and to conduct a comparative benefit assessment of the 3 above-mentioned RAIs compared with each other, in each case in children and adolescents with diabetes mellitus type 1, focusing on patient-relevant outcomes. In addition to the benefit assessment, short-term effects of the interventions investigated were to be presented for the outcomes in the report.
评估门冬胰岛素、谷赖胰岛素或赖脯胰岛素长期治疗的益处，每种药物均与短效人胰岛素治疗进行比较，并对上述三种速效胰岛素类似物（RAIs）相互之间进行比较效益评估，以上评估均针对1型糖尿病儿童和青少年，重点关注与患者相关的结局。除了效益评估外，报告中还将呈现所研究干预措施对各结局的短期影响。
